OTCMKTS:MYRX - Myrexis Stock Price, News & Analysis

$0.0215
0.00 (0.00 %)
(As of 09/19/2019 01:40 PM ET)
Today's Range
$0.0215
Now: $0.0215
$0.0215
50-Day Range
$0.0187
MA: $0.03
$0.03
52-Week Range
$0.0070
Now: $0.0215
$0.0638
Volume1,024 shs
Average Volume6,805 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta3.49
Myrexis, Inc. focuses on identifying, evaluating, and making financial investments in life sciences assets. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MYRX
CUSIPN/A
Phone801-214-7800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees1
Next Earnings DateN/A
OptionableNot Optionable

Receive MYRX News and Ratings via Email

Sign-up to receive the latest news and ratings for MYRX and its competitors with MarketBeat's FREE daily newsletter.


Myrexis (OTCMKTS:MYRX) Frequently Asked Questions

What is Myrexis' stock symbol?

Myrexis trades on the OTCMKTS under the ticker symbol "MYRX."

Has Myrexis been receiving favorable news coverage?

Press coverage about MYRX stock has been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Myrexis earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Myrexis.

Who are some of Myrexis' key competitors?

What other stocks do shareholders of Myrexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myrexis investors own include Histogenics (HSGX), Scivanta Medical (SCVM), Petroteq Energy (PQEFF), Propanc Biopharma (PPCB), VAALCO Energy (EGY), Canopy Growth (CGC), Amarin (AMRN), New Age Brands (NF) and FSD Pharma (HUGE).

Who are Myrexis' key executives?

Myrexis' management team includes the folowing people:
  • Mr. Jonathan M. Couchman, Chairman, CEO, Pres, CFO & Principal Accounting Officer (Age 49)

How do I buy shares of Myrexis?

Shares of MYRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Myrexis' stock price today?

One share of MYRX stock can currently be purchased for approximately $0.0215.

What is Myrexis' official website?

The official website for Myrexis is http://www.myrexis.com/.

How can I contact Myrexis?

Myrexis' mailing address is C/O XSTELOS HOLDINGS INC. 630 FIFTH AVENUE SUITE 2260, NEW YORK NY, 10020. The biopharmaceutical company can be reached via phone at 801-214-7800 or via email at [email protected]


MarketBeat Community Rating for Myrexis (OTCMKTS MYRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  125
MarketBeat's community ratings are surveys of what our community members think about Myrexis and other stocks. Vote "Outperform" if you believe MYRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel